New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.
Often described as inquisitive in her younger years by her father, Dr. Joy Buie always had a keen interest in questions that were more mature than her age. “Even as a child, I was an avid observer of ...
Health insurance can be difficult to understand and sometimes frustrating to handle. We’ve built this page to help you navigate the ins and outs of health insurance options. Here, you’ll find our ...
A new study examined whether urinary biomarkers could predict future kidney complications in individuals with lupus nephritis ...
March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by lupus nephritis – lupus-related kidney disease. Lupus nephritis is a serious ...
The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC) ...
The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...
AstraZeneca reported positive results from a Phase III TULIP-SC clinical trial, showing a statistically significant and clinically meaningful reduction in disease activity with the subcutaneous (SC), ...
A new groundbreaking study has recently identified the link between the long-standing mystery in autoimmune disease: Epstein-Barr Virus (EBV) and how it contributes towards the development of systemic ...
The physical, emotional and financial toll of lupus can be invisible to those who don’t live with this disease. Lupus symptoms affect each person differently, and it can be difficult for those without ...
In this episode, we talk with Dr. Sasha Bernatsky, about lupus and cancer, if there’s a link between lupus and cancer, and a new abstract about cancer incidence and risk factors in a large SLE cohort.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results